Just 6 months into the job, GSK’s CEO is spearheading some big moves. The London-based pharma giant announced Tuesday that it ...
Deal values cancer drug developer Nuvalent at US$124 (RM503) per shareThat is a 40 per cent premium to the US-listed firm’s ...
Collaboration leverages Engitix’s human ECM Platform to identify high-confidence targets for liver fibrosis regressionLONDON, June 08, 2026 (GLOBE NEWSWIRE) -- Engitix Ltd. (“Engitix”), a ...
Chinese drugmaker Jiangsu Hengrui Pharmaceuticals has agreed to develop up to 12 of its drugs with British pharmaceutical giant GSK. Hengrui Pharma granted GSK an exclusive worldwide licence to its ...
GSK has agreed to buy US cancer biotech firm Nuvalent for over $10 billion (£8 billion). The deal gives GSK two late-stage ...
GSK's largest acquisition in recent years, a $10.6 billion purchase of cancer drug developer Nuvalent, signifies a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results